Phase I Clinical Trial of the Wee1 inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase 1 Consortium Report (ADVL1312)

PURPOSE: Adavosertib (AZD1775), an inhibitor of WEE1 kinase, potentiates replicative stress induced by oncogenes or chemotherapy. Anti-tumor activity of adavosertib has been demonstrated in preclinical models of pediatric cancer. This phase I trial was performed to define dose-limiting toxicities (D...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Cole, Kristina A., Pal, Sharmistha, Kudgus, Rachel A., Ijaz, Heba, Liu, Xiaowei, Minard, Charles G., Pawel, Bruce, Maris, John M., Haas-Kogan, Daphne, Voss, Stephan, Berg, Stacey L., Reid, Joel M., Fox, Elizabeth, Weigel, Brenda J.
Formato: Artigo
Idioma:Inglês
Publicado: 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7073289/
https://ncbi.nlm.nih.gov/pubmed/31857431
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3470
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares